Logo image
Sign in
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Journal article

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

M. A. Nauck, M. W. Stewart, C. Perkins, A. Jones-Leone, F. Yang, C. Perry, R. R. Reinhardt and Marc S. Rendell
Diabetologia, Vol.59(2), pp.266-274
02/2016
PMID: 26577795

Metrics

4 Record Views

Details